Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

VX20-147-006

23 evidence topics · 2 sources

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2024-08-02”
Primary completion (actual)“2024-12-20”
Study completion (actual)“2024-12-20”
First posted“2024-07-31”
Last update posted“2025-01-20”
Other study ID numbers“VX20-147-006”
Study design
Design details in the registry record
FieldRegistry entry
Study type“Interventional”
Phase“Phase 1”
Primary purpose“Basic Science”
Allocation“Non-Randomized”
Interventional model“Parallel Assignment”
Masking“None (Open Label)”
Eligibility criteria
Age range and healthy volunteers
FieldRegistry entry
Ages eligible“18 Years to 75 Years”
Sexes eligible“All”
Accepts healthy volunteers“Yes”
Treatment
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
FieldRegistry entry
Enrollment (actual)“36”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Study limitations
Summary: study limitations

VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.